Rishi Kakar

Single-Dose Psilocybin Treatment for Major Depressive Disorder

Charles L. Raison, Gerard Sanacora, Joshua Woolley et al. · JAMA · 2023 · 484 citations · Full text

Medicine, Pharmacology, Psychiatry +11

Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Barbara R. Haight, Susan M. Learned, Céline M. Laffont et al. · The Lancet · 2019 · 284 citations

Nursing, Pharmacology, Pharmacotherapy +11

Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial

Inder Kaul, Sharon Sawchak, Christoph U. Correll et al. · The Lancet · 2023 · 223 citations

Medicine, Pharmacology, Psychiatry +16

A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies

Anke Post, Trevor Smart, Judith Krikke-Workel et al. · Neuropsychopharmacology · 2015 · 100 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder

Sheldon Preskorn, Scott L. Zeller, Leslie Citrome et al. · JAMA · 2022 · 85 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14